Dyax

 

Advancing Novel Biotherapeutics Since 1995®

Press Releases


2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
All Releases
View Summary Dyax Corp. Announces Fourth Quarter and Full Year 2010 Financial Results
Feb 23, 2011
PDF 36.3 KB Add to Briefcase
View Summary Dyax Corp. to Host Fourth Quarter and Year End 2010 Earnings Call and Webcast
Feb 16, 2011
PDF 19.8 KB Add to Briefcase
View Summary Dyax and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema
Jan 10, 2011
PDF 43.6 KB Add to Briefcase
View Summary KALBITOR® (ecallantide) Data Presented at the American College of Allergy, Asthma and Immunology Annual Meeting
Nov 14, 2010
PDF 25.7 KB Add to Briefcase
View Summary Dyax Corp. Announces Third Quarter 2010 Financial Results
Oct 27, 2010
PDF 25.1 KB Add to Briefcase
View Summary Dyax Corp. to Host Third Quarter 2010 Earnings Call and Webcast
Oct 20, 2010
PDF 17.7 KB Add to Briefcase
View Summary Dyax and CMIC Co., Ltd. Announce Partnership to Develop and Commercialize Subcutaneous DX-88 (ecallantide) for Hereditary Angioedema and Other Indications in Japan
Sep 30, 2010
PDF 24.4 KB Add to Briefcase
View Summary Dyax Corp. to Present at September 2010 Investor Conferences
Sep 7, 2010
PDF 18.9 KB Add to Briefcase
View Summary Data from First Phase 3 Trial (EDEMA3®) for KALBITOR® (ecallantide) Published in The New England Journal of Medicine
Aug 5, 2010
PDF 25.4 KB Add to Briefcase
View Summary Dyax Corp. Announces Second Quarter 2010 Financial Results
Jul 28, 2010
PDF 26.1 KB Add to Briefcase
View Summary Dyax Corp. to Host Second Quarter 2010 Earnings Call and Webcast
Jul 21, 2010
PDF 18.8 KB Add to Briefcase
View Summary Dyax Features Comprehensive Financial Assistance Program On Enhanced Product Website for KALBITOR® (ecallantide)
Jul 19, 2010
PDF 29.5 KB Add to Briefcase
View Summary Dyax Announces Marketing Authorization Application for DX-88 (ecallantide) Validated by European Medicines Agency
Jul 6, 2010
PDF 20.2 KB Add to Briefcase
View Summary Dyax and Sigma-Tau Announce Partnership to Develop and Commercialize Subcutaneous DX-88 (ecallantide) for Hereditary Angioedema and Other Indications in Europe, North Africa, Middle East and Russia
Jun 21, 2010
PDF 24.9 KB Add to Briefcase
View Summary Dyax Announces Publication of KALBITOR® (ecallantide) EDEMA4® Trial Results in the Annals of Allergy, Asthma, and Immunology
Jun 7, 2010
PDF 24.9 KB Add to Briefcase
View Summary Dyax Corp. to Present at June 2010 Investor Conferences
Jun 2, 2010
PDF 17.2 KB Add to Briefcase
View Summary Dyax Corp. to Present at the Rodman & Renshaw Annual Global Investment Conference
May 10, 2010
PDF 16.9 KB Add to Briefcase
View Summary Dyax Corp. Announces First Quarter 2010 Financial Results
Apr 28, 2010
PDF 73.9 KB Add to Briefcase
View Summary Dyax Corp. to Host First Quarter 2010 Earnings Call and Webcast
Apr 21, 2010
PDF 17.6 KB Add to Briefcase
View Summary Dyax Corp. Sells Rights to Xyntha® Royalty Stream to Paul Capital Healthcare for up to $12 Million
Apr 20, 2010
PDF 22.3 KB Add to Briefcase
Showing 121-140 of 217 Page: 1 ... 3 4 5 6 7 8 9 10 11  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
 

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?